2014 - 2015年至2016 - 2017年流感季节，四种神经氨酸酶抑制剂（奥司他韦、扎那米韦、拉尼米韦和帕拉米韦）对日本甲型和乙型流感儿童的临床疗效。
Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
作者信息
Ishiguro Nobuhisa, Koseki Naoko, Kaiho Miki, Ariga Tadashi, Kikuta Hideaki, Oba Koji, Togashi Takehiro, Morita Keisuke, Inagawa Akira, Okamura Akiko, Yamazaki Shigeru, Shida Satoru, Konno Mutsuko, Kawamura Nobuaki, Ishizaka Akihito, Takada Kimihiko, Tsubakihara Keiji, Nagano Naoko, Shibata Mutsuo, Furuyama Hideto, Matsuzono Yoshihiro, Koike Akemi, Murashita Mari, Hatae Yoshio, Arioka Hideki, Yamanaka Tatsuru, Watanabe Toru, Tabata Yuuichi, Kumita Yoshihiro, Hazama Kyosuke, Akutsu Yasushi, Aoyagi Hayato, Tobise Chie, Azuma Katsuki, Yasoshima Kohichi, Sawada Yoko, Uetsuji Kazuyuki, Tsuchida Akira, Tsuchiyama Akira, Yasuda Kazue, Odagawa Yasuhisa, Yoshioka Mikio
机构信息
Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan; Department of Pediatrics, Hokkaido Medical Center for Child Health and Rehabilitation, Sapporo, Japan.
出版信息
J Infect Chemother. 2018 Jun;24(6):449-457. doi: 10.1016/j.jiac.2018.01.013. Epub 2018 Feb 24.
The clinical effectiveness of four neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, laninamivir, and peramivir) for children aged 0 months to 18 years with influenza A and B were investigated in the 2014-2015 to 2016-2017 influenza seasons in Japan. A total of 1207 patients (747 with influenza A and 460 with influenza B) were enrolled. The Cox proportional-hazards model using all of the patients showed that the duration of fever after administration of the first dose of the NAI was shorter in older patients (hazard ratio = 1.06 per 1 year of age, p < 0.001) and that the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection (hazard ratio = 2.21, p < 0.001). A logistic regression model showed that the number of biphasic fever episodes was 2.99-times greater for influenza B-infected patients than for influenza A-infected patients (p < 0.001). The number of biphasic fever episodes in influenza A- or B-infected patients aged 0-4 years was 2.89-times greater than that in patients aged 10-18 years (p = 0.010), and the number of episodes in influenza A- or B-infected patients aged 5-9 years was 2.13-times greater than that in patients aged 10-18 years (p = 0.012).
2014 - 2015年至2016 - 2017年流感季期间，在日本对4种神经氨酸酶抑制剂（NAIs）（奥司他韦、扎那米韦、拉尼米韦和帕拉米韦）用于0个月至18岁甲型和乙型流感儿童的临床疗效进行了调查。共纳入1207例患者（747例甲型流感患者和460例乙型流感患者）。使用所有患者数据的Cox比例风险模型显示，NAI首剂给药后发热持续时间在年龄较大的患者中较短（风险比为每1岁1.06，p < 0.001），且甲型流感感染患者NAI首剂给药后的发热持续时间比乙型流感感染患者短（风险比 = 2.21，p < 0.001）。逻辑回归模型显示，乙型流感感染患者双相热发作次数比甲型流感感染患者多2.99倍（p < 0.001）。0 - 4岁甲型或乙型流感感染患者的双相热发作次数比10 - 18岁患者多2.89倍（p = 0.010），5 - 9岁甲型或乙型流感感染患者的发作次数比10 - 18岁患者多2.13倍（p = 0.012）。
Zotero 插件